ClinicalTrials.gg
RecruitingNCT07134010PIT; ACUpdated Sep 4, 2025

The Impact of Perineural Injection Therapy for Adhesive Capsulitis.

An interventional study of perineural injection and Physiotherapy in Adhesive Capsulitis, sponsored by Universiti Teknologi Mara. Recruiting at 1 site in Malaysia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Universiti Teknologi Mara · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if Perineural Injection Therapy (PIT) works to treat adhesive capsulitis (frozen shoulder) in adults. It will also learn about the safety of PIT.

The main questions it aims to answer are:

Does PIT reduce shoulder pain and improve shoulder range of motion more effectively than conventional therapy alone?

What side effects or medical problems do participants experience when receiving PIT?

Researchers will compare PIT to conventional therapy to see if PIT works better to treat adhesive capsulitis.

Participants will:

Receive either:

PIT once weekly for 6 weeks plus physiotherapy and oral analgesics (excluding NSAIDs), or

Conventional therapy only (physiotherapy and analgesics including NSAIDs)

Attend scheduled follow-up visits at Week 6, 1 month, and 3 months after treatment

Perform daily home-based shoulder exercises and record their analgesic use and any side effects in a patient diary

Read the detailed description

Study Title:

The Impacts of Perineural Injection Therapy on Adhesive Capsulitis in a Single Centre Hospital in Selangor: A Randomized Controlled Trial Pilot Study

Study Overview :

Adhesive capsulitis, commonly known as "frozen shoulder," is a painful condition that limits shoulder movement and affects daily activities such as dressing, reaching overhead, or lifting objects. It often affects adults between the ages of 40 to 60 and can last for months or even years. For some, the condition may improve with physiotherapy and medication, but others continue to struggle with pain and stiffness.

This clinical trial aims to explore a new method of treatment called Perineural Injection Therapy (PIT). PIT involves injecting a natural sugar solution (5% dextrose) just under the skin at specific nerve areas around the shoulder. This method targets nerves that may be irritated or inflamed and helps to reduce pain and improve movement.

Although PIT has shown promising results in treating other painful conditions like nerve entrapments and joint pain, its effects on frozen shoulder have not yet been well studied. This research hopes to find out if PIT can help relieve pain, improve shoulder movement, and enhance function in people with frozen shoulder.

The current treatment options for frozen shoulder (such as physiotherapy, painkillers, and steroid injections) do not work for everyone. PIT is a non-surgical option that may help the healing process by calming nerve-related inflammation. This study will evaluate how effective PIT is and whether it is safe for use in treating adhesive capsulitis.

Participants will be randomly assigned to one of two groups:

Intervention Group: Will receive six weekly sessions of PIT combined with physiotherapy and oral pain medication (excluding NSAIDs like ibuprofen).

Control Group: Will receive only conventional therapy, including physiotherapy and standard painkillers (including NSAIDs).

All participants will:

Be evaluated for shoulder pain, range of motion, and ability to perform daily activities at the beginning of the study, at Week 6, 1-month, and 3-months after treatment.

Be taught home exercises to do daily to improve shoulder mobility and strength.

Be asked to keep a diary to record medication use and any side effects they experience.

Receive support and regular follow-ups from the research team to monitor progress and manage any issues.

Adults aged 18 and above who have been diagnosed with primary (idiopathic) adhesive capsulitis for at least 3 months and are experiencing significant shoulder pain and stiffness may be eligible. Participants must be able to understand and follow instructions in Malay or English.

People will not be eligible if they:

Have had a shoulder injection or surgery recently

Have other serious shoulder problems (like a fracture or nerve injury)

Have poorly controlled diabetes or are on certain medications that may interfere with the study

PIT is generally safe and has been used in other conditions with minimal side effects, such as mild pain or redness at the injection site. In this study, participants will be closely monitored for any adverse effects.

Potential benefits include reduced pain, improved shoulder movement, and better overall function. The information gathered may help develop better treatment options for others with frozen shoulder in the future.

Each participant will be involved in the study for approximately 3 to 4 months, including the 6-week treatment period and two follow-up assessments.

02

Conditions studied

  • Adhesive Capsulitis

Browse trials for

Keywords

  • Perineural injection therapy in treating Adhesive Capsulitis
03

In context

Bursitis

384 studies on the registry are indexed under Bursitis; 111 are open to participants now.

This study's planned enrollment of 24 is below the median of 44 across 347 interventional studies indexed under Bursitis.

Browse Bursitis studies →

Lead sponsor

Universiti Teknologi Mara is the lead sponsor of 27 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 and above.
  2. Diagnosed with primary adhesive capsulitis by a specialist.
  3. Limitation of range of motion ≥ 50% relative to the normal side or normal reference (in patient with bilateral adhesive capsulitis) in three or more movement directions (i.e., external rotation, abduction, forward flexion, and internal rotation).
  4. Chronic adhesive capsulitis shoulder pain lasting for at least 3 months.
  5. Pain score of at least 4/10 on the Numerical Rating Scale (NRS) during movement, indicating at least moderate pain severity.
  6. Consented to the study.

Exclusion criteria

Exclusion Criteria:

  1. Received any shoulder pain injection within the past 6 weeks or surgical intervention such manipulation under anesthesia, arthroscopic capsular release, or open surgery for capsular release.
  2. Diagnosed with other shoulder pathology such as neurologic deficits affecting shoulder function, tumour, rotator cuff injury or fracture.
  3. Has history of allergy to dextrose solution.
  4. Patients receiving steroidsimmunosuppressants, psychotropic medication, or other medications that may affect, the clinical outcomes
  5. Patients with haemorrhagic disease, taking anticoagulant drugs, or patients with severe diabetes mellitus having an increased risk of infection ( >8%)
  6. Do not understand Malay or English language.
  7. Unable to follow a 3 steps command.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Perineural injection Therapy

    Other: perineural injection · Other: Physiotherapy

  • Sham comparator
    Conventional group

    Physiotherapy

    Other: Physiotherapy

Interventions

  • Otherperineural injection

    Intervention The procedure will be performed by a rehabilitation physician who has obtained hospital-level credentialing and privileging to practice Perineural Injection Therapy (PIT). The physician has undergone hands-on training with Dr. Lyftogt-certified trainers in Malaysia. PIT will be administered weekly for six week (Total 6 sessions). In addition to this intervention, patient will also receive conventional therapy which is monthly outpatient physiotherapy with supplementary home-based exercise program, and oral analgesia (except NSAIDs). Solution: Buffered 5% dextrose. Pre injection: Chronic constriction injury points will be identified by palpation along the shoulder's cutaneous nerves - the suprascapular, supraclavicular, axillary, musculocutaneous, and radial nerves. These points will be marked to ensure precise targeting. Taking into account these nerve pathways, the maximum injection area for this research is set at 10 sites per session.

    Also known as: Perineural injection therapy, PIT

  • OtherPhysiotherapy

    Patients will be receiving a structured home-based exercise program and will be instructed on how to perform these exercises at home. The exercise regime will be 30 minutes, 3 times a day to enhance shoulder mobility and strength in addition to the regular monthly outpatient physiotherapy session. Oral analgesics exclude NSAIDs will be prescribed as needed to manage pain.

06

What researchers measure

Primary outcomes

  1. Numerical Rating Scale

    Participants will rate their shoulder pain on a scale from 0 to 10, where 0 indicates "no pain" and 10 represents "worst imaginable pain."

    Time frame: Measured at baseline (Week 0), post-treatment (Week 6), 1-month follow-up (Week 10), and 3-month follow-up (Week 18).

  2. Shoulder Range of Motion (ROM)

    Tool: Goniometer (standardized physical measurement) Passive ROM will be measured in four directions: forward flexion, abduction, internal rotation, and external rotation. Values will be recorded in degrees.

    Time frame: Measured at baseline (Week 0), post-treatment (Week 6), 1-month follow-up (Week 10), and 3-month follow-up (Week 18).

Secondary outcomes

  1. Functional Outcome

    Tool: Shoulder Pain and Disability Index (SPADI) - validated English and Malay versions A self-reported questionnaire with 13 items divided into two subscales: 5 for pain and 8 for functional disability. Each item is scored from 0 (no pain/disability) to 10 (worst pain/disability), with higher scores indicating greater impairment.

    Time frame: Measured at baseline (Week 0), post-treatment (Week 6), 1-month follow-up (Week 10), and 3-month follow-up (Week 18).

  2. Adverse Reactions

    Tool: Adverse Event Reporting Form and Patient Diary Description: Side effects will be classified into: Mild: Local pain, bruising, or redness Moderate: Transient numbness, swelling, or prolonged discomfort Severe: Infection or allergic reaction

    Time frame: Monitored throughout the 6-week intervention

Other outcomes

  1. Frequency of Analgesic Use

    Tool: Patient Diary (self-recorded) Description: Participants will log each use of pain medication (type and frequency) throughout the study period.

    Time frame: Recorded weekly from baseline until the 3-month follow-up.

07

Study locations

1 of 1 sites recruiting
  • Hospital Al-Sultan Abdullah, UiTM Puncak Alam
    Kuala Selangor, Selangor 42300, Malaysia
    Recruiting
    • Noor Hafizah Samsudin Bahari, MD(UKM) · Contact2023204074@student.uitm.edu.my · +60333963395
    • Dr Anie Farhana Ngimron, MBBChBAO(Ireland)MRehab(UM) · Contactaniefarhana@uitm.edu.my · +60333963395
    • Assoc. Prof. Dr. Nadia Mohd Mustafah, MD(UPM)MRehab(UM) · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for May 2026, 11 months after the start.

Of 219 non-industry interventional studies with no phase under Bursitis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's planned 11 months is close to that.

Counting every sponsor, half of 219 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 21, 2025
StartActual
Jun 3, 2025
Primary completionEst.
May 31, 2026
CompletionEst.
Jun 1, 2026
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07134010
Lead sponsor
Universiti Teknologi Mara
Responsible party
Noor Hafizah Binti Samsudin Bahari (Medical Doctor, Universiti Teknologi Mara) — Principal investigator
First posted
Aug 21, 2025
Start date
Jun 3, 2025
Primary completion
May 31, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Sep 4, 2025

Study contacts

Noor Hafizah Samsudin Bahari, MD(UKM)
Contact
2023204074@student.uitm.edu.my
+60333963395
Dr Anie Farhana Ngimron, MBBChBAO(Ireland)MRehabMed(UM)
Contact
aniefarhana@uitm.edu.my
+60333963395
Noor Hafizah Samsudin Bahari, MD(UKM)
principal investigator · Faculty of Medicine, Universiti Teknologi MARA, Sg Buloh Campus
Dr Anie Farhana Ngimron, MBBChBAO(Ireland)MRehabMed(UM)
principal investigator · Faculty of Medicine, Universiti Teknologi MARA, Sg Buloh Campus
Assoc. Prof. Dr. Nadia Mohd Mustafah, MD(UPM), MRehabMed(UM)
principal investigator · Faculty of Medicine, Universiti Teknologi MARA, Sg Buloh Campus

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion